We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Inspection of Impax’s Taiwan Facility Reveals Manufacturing Issues

FDA Inspection of Impax’s Taiwan Facility Reveals Manufacturing Issues

August 8, 2014

An FDA inspection of Impax Laboratories’ Taiwan plant has uncovered apparent manufacturing violations, raising new questions about the company’s plans to launch its proposed Parkinson’s disease drug Rytary.

Investigators toured the facility July 21-26 as part of a general inspection and pre-approval check for Rytary (IPX066), the brand and generics maker said.

Among the 10 observations in the resulting Form 483 was Impax’s failure to properly validate equipment used during manufacturing of Rytary, and its failure to reject a June 2013 batch of generic acarbose, despite an unknown impurity found in the end product. Corrective steps made during the course of manufacturing also were not properly documented, the investigators said.

Impax, which makes 12 products at the plant, said it is committed to addressing the observations raised by the FDA. The company noted that the FDA has yet to assign a status or classification to the observations, and won’t do so until it has received its written response.

The company also said it has not been informed by the FDA about how the Form 483 may impact its Rytary NDA, which the agency has until Oct. 9 to review.

The company recently resubmitted the NDA after the FDA had rejected the initial application following manufacturing violations at its Hayward, Calif., facility. Impax’s repeated inability to bring that plant into compliance led GlaxoSmithKline to abandon a marketing partnership for Rytary.

Avoid manufacturing-related Form 483’s. Train your staff on GMP’s the easy way with the Drug GMP Training Course: A 17-Module Customizable Training Series.

Pharmaceuticals Inspections and Audits

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing